Please assess the completion status of the following clinical trial:

Trial Title: Short Versus Extended Antibiotic Treatment With a Carbapenem for High-risk Febrile Neutropenia in Hematology Patients With FUO

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Patients with malignant hematological diseases being treated with cytotoxic chemotherapy or stem cell transplantation;~2. High-risk neutropenia (Absolute neutrophil count (ANC) \<0.5x109/L which is expected to last longer than 7 days);~3. Fever (One single measured tympanic membrane temperature of \>38.5°C or a temperature of \>38.0°C during 2 subsequent measurements separated by at least 2 hours);~4. Age 18 years or older;~5. Written informed consent.~Exclusion Criteria:~1. Contraindications to use of imipenem-cilastatin or meropenem such as allergy, previous severe side-effects or previous microbiological cultures with carbapenem-resistant microorganism(s).~2. Corticosteroid use ≥10 mg per day prednisolone or equivalent for more than 3 consecutive day during the previous 7 days.~3. Clinically or microbiologically documented infection.~4. Symptoms of septic shock (systolic blood pressure \<90 mm Hg unresponsive to fluid resuscitation and/or oliguria (urine production \<500mL/day).~5. Previous enrollment in this study during the same episode of neutropenia.~6. Any critical illness for which Intensive Care Unit treatment is required.~7. Legal incompetency

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Short treatment (Type: EXPERIMENTAL): Discontinuation of imipenem-cilastatin or meropenem after 3x24 hours irrespective of presence of fever.
- Extended treatment (Type: NO_INTERVENTION): Extended treatment with imipenem-cilastatin or meropenem for at least 6 more days. The treatment with a carbapenem will be continued until patients have been treated for at least 9x24 hours and have been afebrile (tympanic membrane temperature \<38.0°C) for at least five consecutive days or until resolution of neutropenia (ANC \> 0,5 x10\^9/L), whichever comes first.

Based on this trial design, predict the completion outcome and termination type (if applicable).